SH3089

SH3089 is an orally bioavailable small molecule inhibitor that specifically targets the G12C mutation of the KRAS (Kirsten rat sarcoma viral oncogene homolog) protein. Developed by Nanjing Sanhome Pharmaceutical, it is designed to treat advanced solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer, where the KRAS G12C mutation acts as a primary driver of malignancy. SH3089 works by covalently binding to the cysteine residue at position 12 of the mutant KRAS protein, effectively trapping it in its inactive, GDP-bound state. This inhibition prevents the activation of downstream signaling cascades, such as the RAF-MEK-ERK pathway, thereby suppressing tumor cell proliferation and survival. The drug is currently being evaluated in Phase 1 clinical trials to determine its safety, pharmacokinetics, and preliminary therapeutic efficacy in patients with KRAS G12C-mutated cancers.